Severe complications from TACE therapy include less than 2 percent of sudden liver failure, gastrointestinal bleeding, 0-6 percent, temporary decrease in liver function. 26-85% and post-embolizatiosyndrome 35-94 percent, with a 6 percent risk of dying patients, do not recommend tace to treat advanced hcc liver cancer patients who spread into the main portal vein due to the risk of complications such as abdominal disease. Gastrointestinal bleeding Bacterial blood or abdominal water and acute renal failure, etc.
การแปล กรุณารอสักครู่..
